2021
Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America
McGinnis KA, Justice AC, Moore RD, Silverberg MJ, Althoff KN, Karris M, Lima VD, Crane HM, Horberg MA, Klein MB, Gange SJ, Gebo KA, Mayor A, Tate JP, Benson C, Bosch R, Kirk G, Marconi V, Colasanti J, Mayer K, Grasso C, Hogg R, Lima V, Montaner J, Sereda P, Salters K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Jacobson J, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Smith G, Loutfy M, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, McGinnis K, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America. Clinical Infectious Diseases 2021, 75: 297-304. PMID: 34609485, PMCID: PMC9410720, DOI: 10.1093/cid/ciab883.Peer-Reviewed Original ResearchMeSH KeywordsAgingCalibrationCohort StudiesFemaleHIVHIV InfectionsHumansMaleMiddle AgedNorth AmericaVeteransConceptsNorth American AIDS Cohort CollaborationVACS Index 2.0National Death IndexHIV-1 RNAHuman immunodeficiency virusCopies/mLRisk of mortalityRace/ethnicityCohort CollaborationNA-ACCORDCause mortalityCD4 countMedian ageDeath IndexImmunodeficiency virusPredicting MortalityMortality ascertainmentMortality rateMortalitySpecific biomarkersPWHDiverse cohortObserved mortalityCohortHIV
2019
Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Althoff KN, Chandran A, Zhang J, Arevalo WM, Gange SJ, Sterling TR, Gill MJ, Justice AC, Palella FJ, Rebeiro PF, Silverberg MJ, Mayor AM, Horberg MA, Thorne JE, Rabkin CS, Mathews WC, Klein MB, Humes E, Lee J, Hogg R, Moore RD, Research and Design of IeDEA N. Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal Of Epidemiology 2019, 188: 2097-2109. PMID: 31602475, PMCID: PMC7036649, DOI: 10.1093/aje/kwz232.Peer-Reviewed Original ResearchConceptsAlcohol-related deathsInjection drug useKey populationsLife expectancyDrug useHuman immunodeficiency virusLife expectancy benefitAge 20 yearsCause of deathCurrent opioid epidemicAlcohol-related mortalityAntiretroviral treatmentImmunodeficiency virusOpioid epidemicExpected life expectancyWhite womenSubstance useWhite menComparison groupDrugsDeathPLWHLife expectancy disparityMenBlack men
2018
Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV
Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 62-72. PMID: 29419568, PMCID: PMC5889316, DOI: 10.1097/qai.0000000000001642.Peer-Reviewed Original ResearchConceptsFramingham risk scoreEffect of abacavirMyocardial infarctionHazard ratioHepatitis C virus infectionType 1Type 2 myocardial infarctionCrude hazard ratioC virus infectionIncident myocardial infarctionInjection drug useHistory of AIDSUse increases riskMarginal structural modelsCohort CollaborationLow CD4Antiretroviral therapyKidney functionMI outcomesTime-dependent confoundingRisk factorsMI occurrenceVirus infectionIncrease riskRisk score
2017
Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 568-576. PMID: 28520615, PMCID: PMC5522001, DOI: 10.1097/qai.0000000000001450.Peer-Reviewed Original ResearchConceptsTraditional CVD risk factorsDetectable HIV RNACVD risk factorsIncidence rateRisk factorsCD4 countHIV RNAMyocardial infarctionCardiovascular diseaseNorth American AIDS Cohort CollaborationType 1 myocardial infarctionHIV-specific factorsLow CD4 countSuppressive antiretroviral treatmentIncidence rate ratiosCohort CollaborationIncident MINA-ACCORDAggressive managementAntiretroviral treatmentMultivariable analysisAtherosclerosis RiskMI riskCommunity cohortGeneral populationCD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors
Muzaale AD, Althoff KN, Sperati CJ, Abraham AG, Kucirka LM, Massie AB, Kitahata MM, Horberg MA, Justice AC, Fischer MJ, Silverberg MJ, Butt AA, Boswell SL, Rachlis AR, Mayor AM, Gill MJ, Eron JJ, Napravnik S, Drozd DR, Martin JN, Bosch RJ, Durand CM, Locke JE, Moore RD, Lucas GM, Segev DL. Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors. American Journal Of Transplantation 2017, 17: 1823-1832. PMID: 28497525, PMCID: PMC5489376, DOI: 10.1111/ajt.14235.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHIV InfectionsHIV SeropositivityHIV-1HumansIncidenceKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedNephrectomyNorth AmericaPrognosisRisk FactorsViral LoadConceptsEnd-stage renal diseaseIncidence of ESRDHIV-positive individualsLive kidney donorsKidney donorsRenal diseaseMultivariable Cox proportional hazards regressionCox proportional hazards regressionPotential live kidney donorsHIV-negative peersHIV-negative participantsHIV-positive participantsProportional hazards regressionCopies/mLKidney donor candidatesCumulative incidence estimatesCohort CollaborationCumulative incidenceHIV infectionViral loadHazards regressionNational HealthPositive individualsIncidence estimatesHealth characteristics
2016
First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013
Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, Gill MJ, Koethe JR, Rebeiro PF, Silverberg MJ, Palella FJ, Patel P, Kitahata MM, Crane HM, Abraham AG, Samji H, Napravnik S, Ahmed T, Thorne JE, Bosch RJ, Mayor AM, Althoff KN, Research and Design F. First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013. Clinical Infectious Diseases 2016, 64: 459-467. PMID: 28172581, PMCID: PMC5850614, DOI: 10.1093/cid/ciw804.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseHuman immunodeficiency virusDiabetes mellitusAntiretroviral therapyCumulative incidenceKidney diseaseNoncommunicable diseasesNorth American AIDS Cohort CollaborationOccurrence of DMType 2 diabetes mellitusRisk of deathDemographic subgroupsNon-black womenCohort CollaborationHIV populationImmunodeficiency virusTreatment optionsHypertensionAge 70Poisson regressionRacial disparitiesDiseaseBlack womenIncidenceCareTime trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era
Park LS, Tate JP, Sigel K, Rimland D, Crothers K, Gibert C, Rodriguez-Barradas MC, Goetz MB, Bedimo RJ, Brown ST, Justice AC, Dubrow R. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era. AIDS 2016, 30: 1795-1806. PMID: 27064994, PMCID: PMC4925286, DOI: 10.1097/qad.0000000000001112.Peer-Reviewed Original ResearchConceptsAntiretroviral therapy eraIncidence rateUninfected personsTherapy eraCohort studyCancer incidenceVeterans Aging Cohort StudyImproved immune functionLarge HIV cohortProspective cohort studyCrude incidence rateIncident cancer diagnosisRisk factor prevalenceAging Cohort StudyEvidence-based screeningIncidence rate ratiosIncidence time trendsFuture cancer incidenceTime trendsHIV/AIDSTrend P valueCancer groupingsSpecific cancer typesART regimensHIV care
2015
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.
Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, Engels EA, Hessol NA, Brooks JT, Burchell AN, Gill MJ, Goedert JJ, Hogg R, Horberg MA, Kirk GD, Kitahata MM, Korthuis PT, Mathews WC, Mayor A, Modur SP, Napravnik S, Novak RM, Patel P, Rachlis AR, Sterling TR, Willig JH, Justice AC, Moore RD, Dubrow R. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Annals Of Internal Medicine 2015, 163: 507-18. PMID: 26436616, PMCID: PMC4711936, DOI: 10.7326/m14-2768.Peer-Reviewed Original ResearchConceptsAge 75 yearsNon-Hodgkin lymphomaCumulative cancer incidenceCumulative incidenceLung cancerKaposi's sarcomaCalendar trendsCohort studyHIV statusHodgkin's lymphomaCancer incidenceLiver cancerNorth American AIDS Cohort CollaborationOral cavity/pharyngeal cancerHigher cumulative incidenceMortality rate trendsCohort CollaborationAnal cancerAntiretroviral therapyPharyngeal cancerSmoking cessationColorectal cancerLifetime riskIncidence trendsUninfected adultsSmoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d’Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015, 29: 221-229. PMID: 25426809, PMCID: PMC4284008, DOI: 10.1097/qad.0000000000000540.Peer-Reviewed Original ResearchConceptsMortality rate ratiosCardiovascular diseaseLife expectancyBackground populationNon-AIDS malignanciesAntiretroviral therapy initiationProportion of smokersNorth American cohortSmoking-related mortalityCause of deathMore life yearsAIDS malignanciesAntiretroviral therapyPrevious smokersTherapy initiationSmoking cessationSmoking increasesExcess mortalityAge 35HIVSmokersAmerican cohortSmokingLife yearsHigh mortality
2014
End-Stage Renal Disease Among HIV-Infected Adults in North America
Abraham A, Althoff K, Jing Y, Estrella M, Kitahata M, Wester C, Bosch R, Crane H, Eron J, Gill M, Horberg M, Justice A, Klein M, Mayor A, Moore R, Palella F, Parikh C, Silverberg M, Golub E, Jacobson L, Napravnik S, Lucas G, AIDS F, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Althoff K, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases 2014, 60: 941-949. PMID: 25409471, PMCID: PMC4357817, DOI: 10.1093/cid/ciu919.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseSex-standardized incidence ratiosRisk of ESRDDiabetes mellitusESRD casesBlack racePredictors of ESRDNorth American AIDS Cohort CollaborationHepatitis C virus coinfectionC virus coinfectionESRD risk factorsIncident ESRD casesHuman immunodeficiency virusHigh viral loadMajority of casesCohort CollaborationVirologic suppressionESRD incidencePrior AIDSRenal transplantViral suppressionInject drugsRenal diseaseVirus coinfectionBlack patientsMortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies
Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JA. Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLOS Medicine 2014, 11: e1001718. PMID: 25203931, PMCID: PMC4159124, DOI: 10.1371/journal.pmed.1001718.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHigh early mortalityEarly mortalityMortality rateAdjusted mortality rate ratioCumulative mortalityDeath registry linkageHIV-1 infectionMortality rate ratiosNorth American cohortSouth African cohortAdvanced diseaseCD4 countRegistry linkageProspective studyVital statusHIV treatmentEuropean cohortPoor ascertainmentHIV-1African cohortAmerican cohortPatientsMortalityCohort
2013
Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug usePredictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection
Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ. Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 149-163. PMID: 23187941, PMCID: PMC3619393, DOI: 10.1097/qai.0b013e31827df36c.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAlanine TransaminaseAnti-Retroviral AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesCreatinineFemaleHemoglobinsHepatitis CHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralSex FactorsConceptsNet reclassification improvementVeterans Aging Cohort Study (VACS) IndexVeterans Affairs Healthcare SystemAntiretroviral therapyPatient subgroupsNorth American AIDS Cohort CollaborationHIV-1 RNA levelsStudy indicesObserved mortalityPrior ART exposureVACS Index scoreHIV-1 RNAImportant patient subgroupsRisk of mortalityHealthcare systemDiverse patient subgroupsCohort CollaborationHIV biomarkersVACS IndexHIV infectionOrgan injuryParametric survival modelsART exposureReclassification improvementC-statistic
2012
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, Monforte A, Vehreschild JJ, Sterne J, Collaboration T. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal Of Epidemiology 2012, 41: 1807-1820. PMID: 23148105, PMCID: PMC3535877, DOI: 10.1093/ije/dys164.Peer-Reviewed Original ResearchConceptsCompleteness of ascertainmentHIV-positive patientsAntiretroviral therapyMortality rateAdult HIV-positive patientsPrevious AIDS diagnosisRates of AIDSAdjusted mortality rateMortality rate ratiosHigher mortality riskHigh mortality rateDiverse patient cohortCohort heterogeneityCohort CollaborationPatient characteristicsHIV treatmentAIDS diagnosisPatient cohortAdjusted ratesClinical careMortality riskCohort characteristicsPatientsDeath ascertainmentCohortRisk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, Kirk GD, D’Souza G, Bosch RJ, Brooks JT, Napravnik S, Hessol NA, Jacobson LP, Kitahata MM, Klein MB, Moore RD, Rodriguez B, Rourke SB, Saag MS, Sterling TR, Gebo KA, Press N, Martin JN, Dubrow R, Research and Design of IeDEA T. Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clinical Infectious Diseases 2012, 54: 1026-1034. PMID: 22291097, PMCID: PMC3297645, DOI: 10.1093/cid/cir1012.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAnal cancer incidence ratesAnal cancer ratesCancer incidence ratesAnal cancerIncidence rateCancer ratesRate ratioMultivariable Poisson regression modelsAntiretroviral therapy eraPoisson regression modelsHIV-InfectedTherapy eraUniversal prevention effortsImmunodeficiency virusCommon cancerCalendar trendsMSMPrevention effortsCancerWomenMenRegression modelsRiskIndividuals
2011
Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America
Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ, AIDS F. Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal Of Epidemiology 2011, 174: 727-735. PMID: 21813792, PMCID: PMC3202147, DOI: 10.1093/aje/kwr141.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug resistanceGenotype testNorth American AIDS Cohort CollaborationHuman immunodeficiency virus drug resistanceGenotypic Resistance Interpretation AlgorithmClinic-based cohortAntiretroviral drug classesAntiretroviral drug resistanceResistance interpretation algorithmsVirus drug resistanceCopies/mLHIV drug resistanceClinical knowledgeDrug resistance mutationsPrevalence of resistanceCohort CollaborationViral loadImmunodeficiency virusAntiretroviral drugsDrug classesClinical carePatientsPrevalenceMultiple imputation method
2009
Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America
Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD, Research and Design N. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases 2009, 49: 1582-1590. PMID: 19845473, PMCID: PMC2871149, DOI: 10.1086/644768.Peer-Reviewed Original ResearchConceptsPlasma HIV RNA levelsCombination antiretroviral therapyHIV RNA levelsVirologic failureRegimen failureHistory of AIDSAntiretroviral therapyTreatment failureHigher plasma HIV RNA levelsAbility of therapyRNA levelsT-cell countsTreatment-naive patientsIndependent risk factorMultivariate Cox regressionAggressive therapeutic interventionMore effective optionsModified therapyHIV infectionCox regressionRisk factorsT cellsSubsequent mortalityMortality rateClinical practiceTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne J, May M, Costagliola D, de Wolf F, Phillips A, Harris R, Funk M, Geskus R, Gill J, Dabis F, Miró J, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 2009, 373: 1352-1363. PMID: 19361855, PMCID: PMC2670965, DOI: 10.1016/s0140-6736(09)60612-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Administration ScheduleEuropeFemaleHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPatient SelectionPractice Guidelines as TopicProportional Hazards ModelsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsHIV-1-infected patientsCombination antiretroviral therapyCD4 cell countAntiretroviral therapyCombination therapyCohort studyCell countCD4 cell count rangeCD4 cell count thresholdAntiretroviral-naive patientsProspective cohort studyHIV Cohort StudyRates of AIDSStart of treatmentHigh mortality rateAbsence of treatmentTiming of initiationDeath eventsCell count thresholdTherapy groupImmediate initiationPatientsMortality rateTherapyAIDS
2006
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet 2006, 368: 451-458. PMID: 16890831, DOI: 10.1016/s0140-6736(06)69152-6.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyCD4 cell countAntiretroviral therapyHazard ratioTreatment responseTreatment-naive HIV-1-infected adultsCell countHIV-1-infected adultsMedian CD4 cell countHIV-1 RNA copiesCharacteristics of patientsHIV-1 RNAShort-term prognosisHIV treatment responseProportion of womenPrimary endpointVirological responseCohort studyHIV infectionCox regressionHAARTPatientsRNA copiesCorresponding figurePrognosis